326 related articles for article (PubMed ID: 29116995)
1. Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis.
Rhodes NJ; Liu J; O'Donnell JN; Dulhunty JM; Abdul-Aziz MH; Berko PY; Nadler B; Lipman J; Roberts JA
Crit Care Med; 2018 Feb; 46(2):236-243. PubMed ID: 29116995
[TBL] [Abstract][Full Text] [Related]
2. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis.
Fawaz S; Barton S; Nabhani-Gebara S
BMC Infect Dis; 2020 Jun; 20(1):430. PubMed ID: 32563242
[TBL] [Abstract][Full Text] [Related]
3. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
Yost RJ; Cappelletty DM;
Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
[TBL] [Abstract][Full Text] [Related]
4. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
5. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Lodise TP; Lomaestro B; Drusano GL
Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
[TBL] [Abstract][Full Text] [Related]
6. Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.
Chan JD; Dellit TH; Lynch JB
J Intensive Care Med; 2018 Feb; 33(2):134-141. PubMed ID: 28486867
[TBL] [Abstract][Full Text] [Related]
7. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III.
Lipman J; Brett SJ; De Waele JJ; Cotta MO; Davis JS; Finfer S; Glass P; Knowles S; McGuinness S; Myburgh J; Paterson DL; Peake S; Rajbhandari D; Rhodes A; Roberts JA; Shirwadkar C; Starr T; Taylor C; Billot L; Dulhunty JM
Crit Care Resusc; 2019 Mar; 21(1):63-68. PubMed ID: 30857514
[TBL] [Abstract][Full Text] [Related]
8. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
Blair K; Covington EW
Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
[TBL] [Abstract][Full Text] [Related]
9. Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Mah GT; Mabasa VH; Chow I; Ensom MH
Ann Pharmacother; 2012 Feb; 46(2):265-75. PubMed ID: 22274145
[TBL] [Abstract][Full Text] [Related]
10. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.
Yang H; Zhang C; Zhou Q; Wang Y; Chen L
PLoS One; 2015; 10(1):e0116769. PubMed ID: 25575030
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.
Falagas ME; Tansarli GS; Ikawa K; Vardakas KZ
Clin Infect Dis; 2013 Jan; 56(2):272-82. PubMed ID: 23074314
[TBL] [Abstract][Full Text] [Related]
15. Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis.
Yang H; Cui X; Ma Z; Liu L
J Pharm Pharm Sci; 2016; 19(2):274-89. PubMed ID: 27518175
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
17. Rationale and evidence for extended infusion of piperacillin-tazobactam.
Kaufman SE; Donnell RW; Hickey WS
Am J Health Syst Pharm; 2011 Aug; 68(16):1521-6. PubMed ID: 21817083
[TBL] [Abstract][Full Text] [Related]
18. Prolonged versus Intermittent Infusion of Antibiotics in Acute and Severe Infections: A Meta-analysis.
Luo J; Liao J; Cai R; Liu J; Huang Z; Cheng Y; Yang Z; Liu Z
Arch Iran Med; 2019 Oct; 22(10):612-626. PubMed ID: 31679364
[TBL] [Abstract][Full Text] [Related]
19. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Arnold HM; Hollands JM; Skrupky LP; Smith JR; Juang PH; Hampton NB; McCormick S; Reichley RM; Hoban A; Hoffmann J; Micek ST; Kollef MH
Ann Pharmacother; 2013 Feb; 47(2):170-80. PubMed ID: 23341160
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
